Abstract
BackgroundAutologous T cells engineered to express a chimeric antigen receptor (CAR) specific for CD19 molecule have transformed the therapeutic landscape in patients with highly refractory leukemia and lymphoma, and the...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have